Abstract:OBJECTIVE:To investigate the expression of CD19 on childhood acute leukemia (AL) and its significance, and to provide evidence for the diagnosis and differential diagnosis as well as monoclonal antibody-targeting treatment of leukemia.METHODS:There were 210 cases of childhood AL, of which 130 cases were male and 80 were female with a mean age of 9 years old. Using a panel of 27 fluorochrome directly labeled monoclonal antibodies, 210 samples from the patients were analyzed with CD45/SSC double parameters and multi-color flow cytometry to determine the expression of CD19.RESULTS:In the 93 cases of B lineage acute lymphoblastic leukemia (ALL), the positive rate (98.9%, 92/93) of CD19 was significantly higher than that of the other B cell related antigens, such as CD10 (88.2%, 82/93, P = 0.003), CD20 (24.7%, 23/93, P = 0.001) and CD22 (60.2%, 56/93, P = 0.001). CD19 was expressed on all 8 cases of B/myeloid (My) hybrid acute leukemia (HAL) and 1 case of B/T HAL, but was not expressed on all 24 cases of T lineage leukemia and 5 cases of T/My HAL. In the 79 cases of acute myeloid leukemia (AML), only 5 (6.3%) cases expressed CD19. The positive rate (6.3%) of CD19 on AML was significantly lower than that on B lineage ALL (98.9%, P = 0.001). The percentage of CD19 positive cells in B/My HAL (41.6% - 88.7% with a mean of 73.8%) was significant higher than that in CD19(+)-AML (21.4% - 50.4% with a mean of 24.2%; Run Sum test, P = 0.0084). Of the 210 cases, 102 were B lineage related AL including B lineage ALL, B/My HAL and B/T HAL. In B lineage related AL, the sensitivity and the specificity of CD19 was 99.0% (101/102) and 95.4% (13/108) while the positive predictive and the negative predictive values to B lineage were 95.3% (101/106) and 99.0% (103/104), respectively. Using CD19(+) as a single reagent to diagnose B lineage, the false positive rate was 4.6% (5/108) and the false negative rate was 1.0% (1/102) with a general diagnosis index (GDI) of 94.4% [GDI = 1-(false positive rate + false negative rate)].CONCLUSION:CD19 is continuously and stably expressed on all stages of B lineage differentiation. It is a reliable cell membrane marker for diagnosing B lineage ALL and an ideal target for antibody-targeting treatment of leukemia as well; the expression degree of CD19 can be used to distinguish B/My HAL from CD19(+)-AML; CD19 didn't express on normal myeloid cells but did on some AML cells. Therefore it can be used to detect the minimal residual disease.

[Expression of SLC25A38 in Leukemic Cells from Children with Acute Lymphoblastic Leukemia].

Overexpression of SLC25A38 Protein on Acute Lymphoblastic Leukemia Cells.

[The Expression of CD19 in 210 Cases of Childhood Acute Leukemia and Its Significance].

Transcriptome-wide subtyping of pediatric and adult T cell acute lymphoblastic leukemia in an international study of 707 cases

High CD38 Expression in Childhood T-cell Acute Lymphoblastic Leukemia is Not Associated with Prognosis.

Prognostic Significance of the Tumor Suppressor Protein P53 Gene in Childhood Acute Lymphoblastic Leukemia.

<i>U2AF1</i> expression is a novel and independent prognostic indicator of childhood T‐lineage acute lymphoblastic leukemia

[Prognostic Value of SLC25A12 Expression in Patients with Acute Myeloid Leukemia Based on Integrated Analysis of Multi-dimensional Clinical Data].

Preliminary Study of VEGF and Its Receptor Expression on Childhood Acute Lymphoblastic Leukemia and Its Relativity to Clinical Manifestations

[Expression and Clinical Significance of Exosome Derived MiR-181b-5p in Children with Acute Lymphoblastic Leukemia]

U2AF1 Expression is a Novel and Independent Prognostic Indicator of Childhood T‐lineage Acute Lymphoblastic Leukemia

Re-Evaluation of Various Molecular Targets Located on Cd34(+)Cd38(-)Lin(-) Leukemia Stem Cells and Other Cell Subsets in Pediatric Acute Myeloid Leukemia

Expression and Clinical Significance of Long Non-coding RNA AC002454.1 in Children with Acute Leukemia

[Expression of IGLL1 Gene and Its Clinical Significance in Pediatric T-ALL].

Overexpression of Lymphoid Enhancer‐binding Factor‐1 (LEF1) is a Novel Favorable Prognostic Factor in Childhood Acute Lymphoblastic Leukemia

Correlation of Plasma MiR-146a,MiR-223 Levels with the Prognosis of Childhood with Acute Lymphoblastic Leukemia

High Expression of SLC27A2 Predicts Unfavorable Prognosis and Promotes Inhibitory Immune Infiltration in Acute Lymphoblastic Leukemia

Expression of Notch1 protein in children with acute leukemia and its significance

Analysis on the immunophenotype of acute leukemia and its clinical significance in children

[Expression of the Transcription Factor PAX5 in Childhood Acute Leukemic Cells].

Immunophenotype and Increased Presence of CD4(+)CD25(+) Regulatory T Cells in Patients with Acute Lymphoblastic Leukemia.